Number of pages: 100 | Report Format: PDF | Published date: March 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
Report Attribute |
Details |
Market Size Value in 2022 |
US$ 1.60 billion |
Revenue Forecast in 2031 |
US$ 3.05 billion |
CAGR |
7.45% |
Base Year for Estimation |
2022 |
Forecast Period |
2023-2031 |
Historical Year |
2021 |
Segments Covered |
Treatment Type, Distribution Channel, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global chronic inflammatory demyelinating polyradiculoneuropathy market was valued at US$ 1.60 billion in 2022 and is expected to register a revenue CAGR of 7.45% to reach US$ 3.05 billion by 2031.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market Fundamentals
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that involves a progressive weakness in arms and legs with reduced sensitivity. The disease is caused due to inflammation in the myelin sheath. Myelin allows nerve fibers to carry signals at high speeds (40-60 meters per second). Myelin loss or injury can cause nerve signal slowdown or blockage, resulting in nerve fiber loss. This leads to muscle weakness, paralysis, and/or impairment of motor function, particularly in the arms and legs. Some research studies suggest that CIDP is the chronic form of acute inflammatory demyelinating polyneuropathy, the most common form of Guillain-Barre Syndrome. Recent research identified antibodies that induce uncommon forms of CIDP (neurofascin 155 and contactin 1) by attacking peripheral nerve components. These results provide the possibility of identification of the root cause of additional types of CIDP.
CIDP can occur at any age and in both genders, but young adult males are more likely to experience it. However, it is more prevalent in the elderly population, mostly in males, than in women. Major symptoms of CIDP include tingling or no sense in fingers, resulting in weakness, fatigue, and loss of deep tendons. Diagnosis of CIDP is complex as symptoms of the disease vary from patient to patient. However, the test that helps with diagnosis involves electromyography and nerve conduction tests. These tests check for very slow nerve conduction velocities and lumbar puncture, looking for high protein levels in spinal fluid without many inflammatory cells. MRI imaging of the nerve roots is also considered for checking the swelling and indications of inflammation.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market Dynamics
The global chronic inflammatory demyelinating polyradiculoneuropathy market is predicted to register growth at a significant pace during the forecast period, due to consistently improving treatment options. The usage of monoclonal antibodies to treat CIDP has garnered significant interest from market players. One of these is rituximab, which is used against immunological-producing lymphocytes (B cells). Rituximab has been proven useful in treating a variety of conditions, including multiple sclerosis and rheumatoid arthritis. Human neonatal Fc receptor (FcRN) inhibitors, which have been helpful in treating myasthenia gravis, are being studied as potential treatments to lower levels of circulating immunoglobulins in CIDP. UCB Biopharma SRL, a German pharmaceutical company, is working on Rozanolixizumab, a humanized monoclonal antibody that binds selectively to the FcRn. It is intended to prevent the interaction of FcRn with IgG, hence reducing IgG recycling and encouraging the elimination of pathogenic IgG autoantibodies.
According to estimates by the National Organization of Rare Disorders, there were 5-7 instances of CIDP per 100,000 people in the United States in 2021. This increasing incidence is influencing market players to launch new drugs in the market. For instance, in February 2021, the U.S. Food and Drug Administration (FDA) approved Pfizer’s Panzyga, an intravenous solution for the treatment of CIDP. Research and development activities for more efficient diagnostic and treatment options by academic institutes for CIDP are projected to further support the market revenue growth during the forecast period.
However, the failure of drugs in clinical trials may hamper the revenue growth of the global chronic inflammatory demyelinating polyradiculoneuropathy market.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market Ecosystem
The global chronic inflammatory demyelinating polyneuropathy market has been analyzed from three perspectives: treatment type, distribution channel, and region.
Chronic inflammatory demyelinating polyradiculoneuropathy market by Treatment Type
Based on the treatment type, the global chronic inflammatory demyelinating polyradiculoneuropathy market has been segmented into corticosteroids, intravenous immunoglobulins, plasma exchange (PE), stem cell transplant, and immunotherapy.
The corticosteroids segment dominated the chronic inflammatory demyelinating polyradiculoneuropathy market with the largest revenue share in 2022. When prescribed in certain doses, corticosteroids help reduce inflammation. This can aid in reducing the symptoms of CIDP. Moreover, corticosteroids can be more effective when combined with other medications, such as immunosuppressive drugs.
Other segments, such as intravenous immunoglobulins (IVIG), plasma exchange (PE), stem cell transplant, and immunotherapy, are expected to show high revenue growth during the forecast period. IVIG can improve the immune system’s effectiveness. Very large IVIG dosages are often needed for the initial treatment of CIDP, and most patients need ongoing intermittent therapy. It has also been demonstrated that PE helps treat CIDP. Immunoglobulins and other immune response elements can be eliminated from the blood, resulting in better relief from the symptoms. Moreover, innovation in PE treatments is also expected to increase the global inflammatory demyelinating polyneuropathy market revenue growth.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market by Distribution Channel
Based on the distribution channel, the global chronic inflammatory demyelinating polyradiculoneuropathy market has been segmented into retail pharmacies, online pharmacies, hospital pharmacies, and others.
The retail pharmacies segment dominated the global chronic inflammatory demyelinating polyradiculoneuropathy market in 2022. This can be primarily attributed to increased consumer demand for convenience and the emergence of new retail pharmacy models. Consumers are increasingly demanding convenience and accessibility regarding their healthcare needs, and retail pharmacies are well-positioned to meet this demand. Digital technologies have also revolutionized the retail pharmacies segment, enabling more efficient and streamlined operations and improving the customer experience. Additionally, newly emerged retail pharmacy models provide specialized services, such as home delivery and on-site clinics, further driving revenue growth in the retail pharmacies segment.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market by Region
Based on the region, the global chronic inflammatory demyelinating polyradiculoneuropathy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America leads the global chronic inflammatory demyelinating polyradiculoneuropathy market owing to the high prevalence of the disease. According to the CIDP foundation, the number of new cases of CIDP in the United States each year is around 1-2 per 100,000 people. Moreover, awareness about the disorder in North America is increasing due to a rise in the number of educational conferences and webinars.
The Asia Pacific chronic inflammatory demyelinating polyradiculoneuropathy market is anticipated to show profitable revenue growth in the forecast years owing to improving healthcare standards and rising government initiatives. In addition, the growing number of diagnostic centers and the availability of better healthcare services are expected to propel the revenue growth of the market in the Asia Pacific. Furthermore, increase in research and development activities is anticipated to drive rapid development in the Asia Pacific chronic inflammatory demyelinating polyradiculoneuropathy market.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market Competitive Landscape
The prominent players in the global chronic inflammatory demyelinating polyradiculoneuropathy market include:
The growing availability of improved treatment options and improving diagnosis rates are fueling revenue growth in the global chronic inflammatory demyelinating polyradiculoneuropathy market.
Mylan N.V., Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Sanofi S.A., and GSK plc are among the top market players.
The intravenous immunoglobulins and plasma exchange segments are anticipated to grow at a rapid pace during the forecast period.
The market in Asia Pacific is expected to mark the highest revenue growth during the forecast period.
The high cost of treatments and stringent regulations are the most prominent restraints in the global chronic inflammatory demyelinating polyneuropathy market.
*Insights on financial performance are subject to availability of the information in the public domain